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Angiotensin II synergizes with 
BAFF to promote atheroprotective 
regulatory B cells
Padmapriya Ponnuswamy1, Jeremie Joffre1, Olivier Herbin1, Bruno Esposito1, Ludivine 
Laurans1, Christoph J. Binder3, Thomas F. Tedder2, Lynda Zeboudj1, Xavier Loyer1, Andreas 
Giraud1, Yujiao Zhang1, Alain Tedgui1, Ziad Mallat1,4 & Hafid Ait-Oufella1,5
Angiotensin II (AngII) promotes hypertension, atherogenesis, vascular aneurysm and impairs post-
ischemic cardiac remodeling through concerted roles on vascular cells, monocytes and T lymphocytes. 
However, the role of AngII in B lymphocyte responses is largely unexplored. Here, we show that chronic 
B cell depletion (Baffr deficiency) significantly reduces atherosclerosis in Apoe−/− mice infused with 
AngII. While adoptive transfer of B cells in Apoe−/−/Baffr−/− mice reversed atheroprotection in the 
absence of AngII, infusion of AngII in B cell replenished Apoe−/−/Baffr−/− mice unexpectedly prevented 
the progression of atherosclerosis. Atheroprotection observed in these mice was associated with a 
significant increase in regulatory CD1dhiCD5+ B cells, which produced high levels of interleukin (IL)-
10 (B10 cells). Replenishment of Apoe−/−/Baffr−/− mice with Il10−/− B cells reversed AngII-induced 
B cell-dependent atheroprotection, thus highlighting a protective role of IL-10+ regulatory B cells 
in this setting. Transfer of AngII type 1A receptor deficient (Agtr1a−/−) B cells into Apoe−/−/Baffr−/− 
mice substantially reduced the production of IL-10 by B cells and prevented the AngII-dependent 
atheroprotective B cell phenotype. Consistent with the in vivo data, AngII synergized with BAFF to 
induce IL-10 production by B cells in vitro via AngII type 1A receptor. Our data demonstrate a previously 
unknown synergy between AngII and BAFF in inducing IL-10 production by B cells, resulting in 
atheroprotection.
Despite decades of research and availability of various cholesterol lowering drugs, atherosclerosis remains the 
major cause of mortality in the world. Beyond the undisputable role of low-density lipoproteins (LDL) in disease 
initiation1, a substantial body of evidence point to an important role of immune mediated mechanisms in disease 
progression2, 3. Central to both atherosclerosis initiation and progression is the renin-angiotensin system, which 
plays a crucial role through several distinct mechanisms4. Angiotensin II (AngII), generated from Angiotensin 
I by Angiotensin Converting Enzyme (ACE), is the primary effector molecule of the renin-angiotensin system 
and is known to cause vascular cell dysfunction/activation, predisposing the vascular wall to inflammatory cell 
recruitment5–7. AngII controls various physiological and pathological functions8, and its role has been extended 
to the innate and adaptive immune systems where it modulates macrophage polarization9, T lymphocyte acti-
vation10, and the balance of helper T cell subsets11. Other studies unveiled a pivotal immune-modulatory role 
of the renin-angiotensin system in autoimmune diseases and in patients with heart failure12, 13. In those studies, 
blockade of AngII signaling suppressed auto-reactive Th1 and Th17 responses, promoted regulatory T cells12, or 
led to reduction of Th1/Th2 ratio and inflammatory cytokine production13.
AngII-induced atherosclerosis is mediated through type 1A receptor (Agtr1a) signaling in vascular cells14. 
Invalidation of AngII signalling in bone marrow-derived leukocytes plays a minor role14 suggesting distinct 
roles of AngII on immune cell subsets. Indeed, while AngII induces T cell activation and proliferation, Agtr1a 
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activation in macrophages has recently been shown to suppress their M1 pro-inflammatory phenotype, provid-
ing a protection in a mouse model of kidney injury15. The effects of AngII on B cell functions remain unknown. 
In the last decade, B cells were considered atheroprotective16, 17. More recently, we and others have reconsidered 
and redefined the role of B cells in atherosclerosis18, 19. The natural IgM secreting B1a subset was indeed shown to 
be atheroprotective20, 21. Conversely however, depletion of mature B2 cells using CD20 monoclonal antibody or 
genetic B2 cell deficiency in Baffr−/− mice resulted in reduced lesion development, indicating a proatherogenic 
role of the B2 cell subset18, 19, 22. The results are consistent with the pro-atherogenic role of T follicular helpher/
germinal center B cell activation23. Still, the B2 cell subset is a heterogeneous population of folicular B cells, 
innate-like marginal zone B cells and regulatory B cells (Bregs) with distinct developmental and (patho)physio-
logical functions, and their selective roles in modulating the immune response during atherosclerosis are yet to 
be defined. Two studies recently addressed the role of regulatory B cells in hyperlipidemia-associated vascular 
disease. While we showed that endogenous IL-10 producing B cells do not alter the development of atheroscle-
rosis in hypercholesterolemic Ldlr−/− mice24, another study reported IL-10-dependent protection against neoin-
tima formation after exogenous supplementation with lymph node-derived regulatory B cells25. The discrepancy 
between the two studies can be explained by important differences in the disease models and the source, state 
of activation and function of the B cells used in the experiments. Thus, additional studies are required to better 
understand the mechanisms that promote the development and maintenance of atheroprotective regulatory B 
cells. We became interested in a recent study by Saussine et al. that reported high levels of IL-10 producing B 
cells in active sarcoidosis, a finding that was associated with elevated levels of BAFF and ACE activity26. Given 
the importance of ACE activity in patients with coronary artery disease27, we attempted to understand the role 
of AngII (in combination with BAFF) in modulating B cell-mediated immune responses. We used Apoe−/− mice 
infused with AngII, a well-established model of AngII-induced vascular disease, to understand the role of AngII 
in modulating B cell function during the development of atherosclerosis. To address the selective effect of AngII 
on B2 cells, we adoptively transferred mature B cells into B2 cell-deficient Apoe−/−/Baffr−/− mice. The Apoe−/−/
Baffr−/− model also has the advantage of displaying high levels of BAFF, and is particularly suited to address 
the impact of the interaction between AngII and BAFF on the function of mature B cells. Here, we report the 
surprising finding that AngII signals through Atgr1a on B cells to induce a B10 regulatory and anti-atherogenic 
phenotype, particularly in a high BAFF environment.
Materials and Methods
Animals. Experiments were conducted according to the European Community for experimental animal 
use guidelines (L358-86/609EEC) and were approved by the Ethical Committee of INSERM. All mice used in 
the experiments were male on a C57BL/6J background and maintained on a chow diet. Baffr−/−, Il10−/− and 
Agtr1a−/− mice were obtained from Jackson Laboratories and were backcrossed more than 10 generations into 
a C57BL/6J background. CD45.1 and Apoe−/− mice were from Charles River. Apoe−/− mice were crossed with 
Baffr−/− mice to generate Apoe−/−/Baffr−/− mice. B cells were isolated from Wild-type (WT, C57BL/6J), Il10−/− or 
Agtr1a−/− mice using negative isolation kit from Miltenyi, according to manufacturer’s protocol. Recipient mice 
were injected with ~30 × 106 B cells 3–6 weeks before AngII infusion. AngII was infused subcutaneously in 12–14 
weeks old mice via osmotic pumps at the concentration of 1 μg/kg/min for 7 or 28 days.
Atherosclerotic lesion. Atherosclerotic lesion assessment was performed on aortic sinus sections of mice 
infused with AngII for 28 days or in similar age matched controls without AngII infusion. Animals that died 
before 28 days of AngII (or PBS) infusion were not analyzed. Plasma cholesterol was measured using a com-
mercial cholesterol kit (Sigma). Quantification of lesion size was performed as described earlier18. In brief, the 
basal half of the ventricles and the ascending aorta were perfusion-fixed in situ with 4% paraformaldehyde. After 
then, they were removed, transferred to a PBS-30% sucrose solution, embedded in frozen OCT and stored at 
−70 °C. Serial 10-μm sections of the aortic sinus with valves (80 per mouse,) were cut on a cryostat, as previously 
described28. Of every 5 sections, one was kept for plaque size quantification after Oil red O staining. Thus, 16 sec-
tions spanning 800 μm stretch of the aortic root were used to determine mean lesion area for each mouse. Oil Red 
O positive lipid contents were quantified by a blinded operator using HistoLab software (Microvisions). Plasma 
cholesterol was measured using a commercial cholesterol kit (Biomerieux).
Systolic Blood Pressure Measurement. Systolic Blood Pressure (SBP) was measured in conscious mice 
using a tail cuff system (BP-2000 Visitech Systems), as previously described29. Measurements were always per-
formed in the morning. In each animal, the system automatically performed 4 measurements first, which were 
not recorded, then, 10 consecutive measurements of SBP that were recorded. To avoid procedure-induced anxiety, 
and in each series of experiments, mice were accustomed to the tail cuff system during 3 consecutive days before 
basal SBP was recorded for 2 to 3 days (values were averaged) just prior mini-pump implantations. Then, SBP was 
measured at days 7, 14, 21 and 28, post-implantation.
Cell culture. B cells were isolated from splenocytes by negative selection using a cocktail of antibody coated 
magnetic beads (Miltenyi Biotec, Germany), and the purity was confirmed to be >95%. Purified B cells were 
stimulated in vitro with anti-CD40/IgM or LPS for 72 h. The supernatant was stored for ELISA, and for intracel-
lular staining of IL-10, the cells were stimulated with a leukocyte activation cocktail containing golgi stop for the 
last 5 hours of culture before flow cytometric analysis.
Flow Cytometry. Single cell preparations of murine splenocytes were stained with the following flu-
orochrome conjugated antibodies: CD19-APC (clone: 1D3) B220-Amcyan (Clone: RA3-6B2), CD5-APC 
(Clone: 53–7.3), CD44-APC (Clone: IM7), CD45.1-PerCP-Cy5.5 (Clone: A20), CD4-FITC (Clone: RM4-5), 
CD3-PerCP-Cy5.5 (Clone: 145-2C11), CD23-PE (Clone: B3B4), CD21-PECy7 (Clone: 7G6), CD1d-Brillant 
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Violet 450 (Clone: 1B1). For intracellular cytokine staining, lymphocytes were stimulated in vitro with leukocyte 
activation cocktail (BD) according to the manufacturer’s instructions for 4 h. Surface staining was performed 
before permeabilization using an intracellular staining kit (eBioscience). Intracellular IL-10 and IFN-γ was 
detected using IL-10-APC (Clone: JES5-16E3) and IFNγ-FITC (Clone: XMG1.2) antibodies, respectively.
ELISA. B cells were isolated from Apoe−/− and Apoe−/−/Baffr−/− mice transferred with B cells with or without 
AngII for 7 days or 28 days. Isolated B cells were stimulated in vitro with LPS or anti-CD40/IgM to determine 
IL-10 production. Cell free culture supernatants were frozen at −80 °C and then later examined for IL-10 pro-
duction using a BD mouse IL-10 ELISA kit. sBAFF was determined by ELISA (R&D Systems) in the plasma sam-
ples from Apoe−/− and Apoe−/−/Baffr−/− mice with or without B cell transfer. Circulating antibody titers against 
MDA-LDL and CuOx-LDL were determined by chemiluminescent ELISA, as previously described30–32.
qPCR. RNA was isolated from B cells from Apoe−/−/Baffr−/− mice transferred with B cells with or without 
AngII infusion. B cells isolated from WT or Agtr1a−/− mice were treated in vitro with AngII (10 μMol) for 72 hours 
with or without pre-treated with AT1a antagonist, Valsartan (10 μMol) or pErk inhibitor, PD98.059 (10 μMol) for 
two hours before stimulation with AngII. After 72 hours of in vitro stimulation, RNAs were extracted from B cells 
using Trizol reagent. In experiments where Apoe−/−/Baffr−/− mice were transferred with CD45.1+ B cells, the 
transferred B cells (CD45.1+) and the resident B cells (CD45.1−) were sorted using flow cytometry after 7 days 
of AngII infusion and the sorted cells were used for RNA isolation. cDNA was synthesised according to Qiagen 
reverse Transcription kit. Quantitative real-time PCR (Q-PCR) was performed on an ABI Prism 7700 (Applied 
Biosystems) in triplicates. CT for Gapdh (primers: Gapdh R, 5′-CGTCCCGTAGACAAAATGGTGAA-3′; 
Gapdh L, 5′-GCCGTGAGTGGAGTCATACTGGAACA-3′) was used to normalize gene expression. Primer 
sequences for Il10 and Agtr1a were as follows: Il-10 Forward: 5′-AAGTGATGCCCCAGGCA-3′, Il10 Reverse: 
5′-TCTCACCCAGGGAATTCAAA-3′, Agtr1a Forward 5′-AAC AGC TTG GTG GTG ATC GTC-3′, Agtr1a 
Reverse: 5′-CAT AGC GGT ATA GAC AGC CCA-3′.
Statistics. All data are expressed as mean ± SE. Comparisons of 2 different groups were analyzed by 
Mann-Whitney U test. ANOVA test with Bonferroni’s post-test analysis was used for more than 2 groups. Statistical 
analyses were performed with Prism 5 software (GraphPad). P values < 0.05 was considered statistically significant.
Results
AngII promotes atheroprotective regulatory B cells. B2 cells promote experimental atherosclerosis. 
Here, we aimed to investigate the role of B cells in athero-prone mice infused with AngII, which mimics some 
clinical situations in patients with coronary artery disease who may display increased ACE activity27. As pre-
viously reported in mice without AngII infusion18, treatment of Apoe−/− mice with anti-CD20 B cell-depleting 
monoclonal antibody also resulted in a significant reduction of atherosclerosis in mice infused with AngII for 
28 days (Supplementary Fig. S1a), with no difference in plasma total cholesterol levels (Supplementary Fig. S1b). 
Consistent with acute B cell depletion, chronic B2 cell deficiency in Apoe−/−/Baffr−/− mice (Supplementary Fig. S2) 
reduced the development of atherosclerosis compared to Apoe−/− mice, both in the absence and presence of AngII 
(Fig. 1a,b). Based on these results, we hypothesized that transfer of B cells into Apoe−/−/Baffr−/− mice would 
reverse atheroprotection. We therefore supplemented Apoe−/−/Baffr−/− mice with purified splenic CD19+IgM+ 
B cells (Supplementary Fig. S3). Replenishment of Apoe−/−/Baffr−/− mice with wild-type B cells (WT, C57BL/6J) 
reversed the atheroprotective effects of B cell deficiency in the absence of AngII infusion, resulting in increased 
lesion formation (Fig. 1a). These results are consistent with the pro-atherogenic role of Baff receptor signaling in 
B cells19. However, to our surprise, adoptive transfer of B cells did not alter the development of atherosclerosis in 
Apoe−/−/Baffr−/− mice infused with AngII (Fig. 1b). Similar results were obtained when Apoe−/−/Baffr−/− mice 
were replenished with Apoe−/− B cells and infused with AngII (data not shown). Adoptive transfer of B cells in the 
presence or absence of AngII infusion did not have any effect on plasma total cholesterol levels (Supplementary 
Fig. S4). Moreover, transfer of B cells did not affect the blood pressure response to AngII (Supplementary Fig. S5). 
In another series of experiments, we found that AngII infusion was able to increase the development of atheroscle-
rosis in the aortic sinus of Apoe−/−Baffr−/− mice. However, replenishment of Apoe−/−Baffr−/− mice with wild type B 
cells completely abolished the atherogenic effect of AngII infusion (Supplementary Fig. S6). Thus, our data indicate 
that the presence of AngII impairs the pro-atherogenic effect of B cells.
Recent studies reported a role for IgM secreting B1a B cells in atheroprotection20. Chronic B cell deficiency resulted 
in a significant reduction of anti-oxLDL IgG and IgM antibodies, and adoptive transfer of B cells restored the levels of 
both IgG and IgM anti ox-LDL antibodies, independently of AngII infusion (Supplementary Fig. S7). Moreover, we did 
not find any difference in peritoneal B1a B cell numbers between the various groups of mice (data not shown).
Our flow cytometry analysis of splenocytes following B cell transfer demonstrated significant replenishment of 
the major B2 cell subsets (follicular and marginal zone B cells) in Apoe−/−/Baffr−/− mice (Figs 2a and S8). Notably 
however, B cell transfer was associated with a significant increase of CD1dhiCD5+ regulatory B cell subset only in 
mice infused with AngII (Figs 2b and S9). Further analysis of the immune response revealed a significant increase 
of CD4+ T cell activation and cytokine (IFN-γ/IL-17/IL-10) production after B cell transfer in the absence of 
AngII. In contrast, B cell transfer did not lead to any T cell activation in the presence of AngII (Figs 2c,d, S10 
and S11). B cell supplementation into Apoe−/−/Baffr−/− mice did not significantly affect CD4+CD25highFoxp3+ 
regulatory T cell population, regardless of AngII infusion (data not shown). Collectively, these results point to 
an unexpected function of AngII in promoting atheroprotective regulatory B cells. Since the effect is observed 
in a context of high BAFF levels (Apoe−/−/Baffr−/−), we suspected a synergistic effect between AngII and BAFF.
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AngII and BAFF synergistically induce IL-10 production in B cells. Next, we investigated if the 
increase of CD1dhiCD5+ B cells in Apoe−/−/Baffr−/− mice following AngII infusion was due to an expansion 
of endogenous immature residual B cells or to the population of adoptively transferred B cells being polarized 
toward a regulatory phenotype. To answer this question, we transferred CD45.1 splenic B cells into Apoe−/−/
Baffr−/− mice with or without AngII infusion for 7 days. We found a significant increase of CD1dhiCD5+ B cells 
in the AngII infused group (Fig. 3a). Consistent with a regulatory CD1dhiCD5+ phenotype, AngII also induced 
IL-10 production in B220+/CD19+ B cells (Figs 3b and S12, and data not shown), and CD1dhiCD5+ B cells 
(Supplementary Fig. S13), but not in B1 cells (Supplementary Fig. S14). Amongst the transferred CD45.1+ B cells 
in Apoe−/−/Baffr−/− mice, IL-10 levels were significantly higher in the mice infused with AngII (Fig. 3c), suggest-
ing that the transferred mature B cells produced IL-10 upon AngII stimulation. Our results were verified by qPCR 
(Figs 3d and S15) and by ELISA (Fig. 3e).
Interestingly, we also observed a significant increase of IL-10 production in Apoe−/−/Baffr−/− mice transferred 
with B cells in the absence of AngII, although to a lower extent compared with AngII-treated mice (Figs 3b, S12 
and S16). In fact, Baffr deficiency results in a significant increase of serum BAFF levels (Supplementary Fig. S17) 
and recent studies demonstrated that both murine and human B cells can be induced to produce IL-10 upon 
stimulation with BAFF33, 34. We therefore addressed the potential synergy between AngII and BAFF in promoting 
a B10 phenotype. We transferred B cells to either Apoe−/− mice (‘normal’ plasma BAFF levels) or Apoe−/−/Baffr−/− 
mice (elevated BAFF levels), and treated the mice with PBS or AngII for 7 days. Our flow cytometry analysis of 
splenocytes from these mice showed a significant increase of IL-10 production by B cells, especially in B cell 
replenished Apoe−/−/Baffr−/− mice with AngII infusion (Supplementary Fig. S12b). Our ELISA results showed 
that there was a significant increase of IL-10 production in AngII infused Apoe−/− mice; however, IL-10 produc-
tion was more pronounced in Apoe−/−/Baffr−/− mice infused with AngII (Supplementary Fig. S16), revealing a 
synergy between AngII and BAFF in the induction of B10 cells.
Regulatory B cells generated in response to AngII are atheroprotective through their produc-
tion of IL-10. We hypothesized that AngII-induced regulatory B cells prevented the progression of ather-
osclerosis through their IL-10 production. To test this hypothesis, we re-supplemented Apoe−/−/Baffr−/− mice 
Figure 1. B cell deficiency reduces AngII induced atherosclerosis but adoptive transfer of B cells does not 
reverse atheroprotection in mice infused with AngII. (a) Representative pictures (left), quantitative lesion 
assessment by Oil Red O staining in the aortic sinus (right) of Apoe−/− and Apoe−/−/Baffr−/− mice with or 
without B cell transfer infused with PBS for 28 days (Apoe−/−, n = 15; Apoe−/−/Baffr−/−, n = 15; Apoe−/−/
Baffr−/− + B cells, n = 17). PBS was infused in 8-week old mice during 28 days. B cell supplementation was 
carried out 3 weeks before PBS infusion in one Apoe−/−/Baffr−/− group. (b) Representative pictures (left) 
and quantitative lesion assessment by Oil Red O staining in the aortic sinus (right) of Apoe−/− and Apoe−/−/
Baffr−/− mice transferred with B cells in the presence of AngII (Apoe−/−, n = 12; Apoe−/−/Baffr−/−, n = 9; 
Apoe−/−/Baffr−/− + B cells, n = 7). AngII (1 µg/kg/min) was infused in 8-week old mice during 28 days. B cell 
supplementation was carried out 3 weeks before AngII infusion in one Apoe−/−/Baffr−/− group. *p < 0.05, 
**p < 0.01, n.s denotes non significance. Scale bar 200 μm.
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with either Il-10+/+ or Il-10−/− B cells, followed by AngII infusion for 28 days. Adoptive transfer of Apoe−/−/
Baffr−/− mice with Il-10−/− B cells did not alter BAFF levels (Supplementary Fig. S17b) but resulted in a signifi-
cant reduction of IL-10 production in splenocytes (Fig. 4a), splenic B cells (Figs 4b and S18) and CD1dhiCD5+ B 
cells (data not shown), and was associated with a significant acceleration of atherosclerosis (Fig. 4c). These results 
demonstrate that AngII induced B10 cells are endowed with atheroprotective properties.
Agtr1a deficiency in B cells abrogates the atheroprotective B10 phenotype. Agtr1a is known to 
mediate several biological effects of AngII35, 36. In accordance with a previous publication10, we observed Agtr1a 
gene expression in splenic purified B cells (Fig. 5a). We therefore investigated if the AngII-induced atheroprotec-
tive effects of B cells were mediated by Agtr1a. Adoptive transfer of Agtr1a−/− B cells into AngII infused Apoe−/−/
Baffr−/− mice abrogated the atheroprotection observed in Apoe−/−/Baffr−/− mice transferred with WT B cells, 
despite no changes in plasma total cholesterol levels (Fig. 5b,c). We also observed a significant 38% reduction of 
IL-10 production by B cells (Figs 5d, S19 and S20) in mice transferred with Agtr1a−/− B cells. In vitro stimulation 
of WT B cells with AngII induced Il-10 mRNA, which was abrogated by Agtr1a deficiency and by valsartan, an 
antagonist of Agtr1a (Fig. 5e). We further attempted to understand the pathway through which Agtr1a induces 
IL-10 production. ERK activation is critical for the induction of IL-10 in many cell types37 and AngII is known to 
induce the ERK pathway38, 39. Accordingly, ERK inhibition using PD98.059 abolished AngII induced Il-10 mRNA 
Figure 2. AngII infusion promotes regulatory B cells in B cell replenished Apoe−/−/Baffr−/−mice. (a) 
Representative dot plots and quantitative analysis of flow cytometry staining of splenic B cell populations. 
Marginal zone (MZ) B cells are defined as CD21hiCD23− population and follicular B cells (FO) are defined 
as CD21+CD23+ population amongst B220+ cells. Adoptive transfer of Apoe−/−/Baffr−/− mice with B 
cells without (left) or with (right) AngII demonstrates replenishment of all B cell subsets. n = 6–8 mice 
per group. ***p < 0.001. (b) Representative dot plots and quantitative analysis of facs staining of splenic 
regulatory CD1dhiCD5+ B cells gated on B220+ cells in Apoe−/−/Baffr−/− mice with or without adoptive B 
cell transfer, infused with PBS for 28 days (left) and their age matched controls with AngII infusion (right). 
(c) Representative FACS examples and quantitative analysis of splenic CD44hi cells amongst CD4+ T cells in 
Apoe−/−/Baffr−/− mice with or without adoptive B cell transfer, infused with PBS for 28 days (left) and their age 
matched controls with AngII infusion (right). (d) Representative examples and quantitative analysis of splenic 
IFN-γ+ cells amongst CD4+ T cells by intracellular facs staining in Apoe−/−/Baffr−/− mice with or without 
adoptive B cell transfer, infused with PBS for 28 days (left) and their age matched controls with AngII infusion 
(right). n = 6–8 mice per group. *p < 0.05, **p < 0.01, ***p < 0.001, ns denotes non significance.
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expression in B cells (Fig. 5e). Our results identify a previously unsuspected role for AngII in inducing IL-10 
production by B cells through Agtr1a-dependent activation of ERK.
Discussion
The present study reveals a synergistic effect between AngII and BAFF in inducing atheroprotective B10 cells via 
AT1A receptor. Our conclusion is supported by four major findings. First, adoptive transfer of B cells in Apoe−/−/
Baffr−/− mice reversed the atheroprotective effect of B cell deficiency only in the absence of AngII infusion. 
Second, AngII infusion led to a profound increase of the regulatory CD1dhiCD5+ B10 subset and its production of 
IL-10. Third, replenishment of Apoe−/−/Baffr−/− mice with Il-10−/− B cells broke the resistance to atherosclerosis 
observed in AngII-infused Apoe−/−/Baffr−/− mice replenished with Il-10+/+ B cells. Finally, AngII induced IL-10 
production by B cells was significantly attenuated by Agtr1a deficiency, and transfer of Apoe−/−/Baffr−/− mice 
with Agtr1a−/− B cells in the presence of AngII led to increased atherosclerosis compared with the transfer of 
Agtr1a+/+ B cells.
Consistent with previous reports on the pro-atherogenic role of BAFF receptor signaling in B cells18, 19, 21, we 
observed that replenishment of Apoe−/−/Baffr−/− mice with mature B cells significantly promoted atherosclerosis. 
However, to our surprise replenishment of Apoe−/−/Baffr−/− mice with mature B cells in did not reverse athero-
protection when mice were infused with AngII. Consistent with this finding, AngII infusion increased atheroscle-
rosis in the aortic sinus of Apoe−/−/Baffr−/− mice but AngII pro-atherogenic effect was lost in mice replenished 
with mature B cells. Recent published studies have shown differential roles of B cell subsets in the development 
Figure 3. Adoptively transferred B cells in Apoe−/−/Baffr−/− mice produced IL10 following AngII infusion. 
(a–c) B cells isolated from Apoe−/−/Baffr−/− mice without or with AngII infusion for 7 days in the presence or 
absence of adoptively transferred CD45.1 B cells were stimulated ex vivo with anti-CD40/anti-IgM. n = 4 per 
group. (a) Quantitative analysis (left) and representative dot plots (right) of CD1dhiCD5+ regulatory B cells 
gated on B220+ population shows a significant increase in regulatory B cell population in mice infused with 
AngII for 7 days. (b) Quantitative analysis (left) and representative dot plots (right) of intracellular IL10 staining 
in B cells gated on B220+ population shows a significant increase in B10 cells in mice infused with AngII for 
7 days. (c) Mean fluorescence intensity of IL10 staining gated on CD19+ CD45.1− resident B cells and CD19+ 
CD45.1+ transferred B cells from Apoe−/−/Baffr−/− mice adoptively transferred with CD45.1 B cells and infused 
without or with AngII infusion. n = 4–5 per group. (d) Quantitative analysis of Il10 mRNA expression from 
resident CD45.1− and transferred CD45.1+ B cells isolated from Apoe−/−/Baffr−/− mice adoptively transferred 
with CD45.1 B cells and infused without or with AngII infusion. n = 4–5 per group. (e) Splenic B cells isolated 
from Apoe−/−/Baffr−/− mice without or with AngII infusion for 7 days in the presence or absence of adoptively 
transferred CD45.1 B cells were stimulated ex vivo with LPS to detect soluble IL10 levels by ELISA. n = 4 per 
group. *p < 0.05, **p < 0.01, ****p < 0.001.
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of atherosclerosis. While mature B2 cells are shown to be proatherogenic, the IgM secreting B1a subset is shown 
to be atheroprotective20, 22. The latter subset was unlikely to be involved in the AngII-dependent atheroprotective 
B cell phenotype because restoration of (anti-oxLDL) IgM antibody levels following B cell transfer in Apoe−/−/
Baffr−/− mice was comparable in mice with or without AngII. Though adoptive transfer of mature B cells in 
Apoe−/−/Baffr−/− mice led to similar restoration of B cell subsets in presence or absence of AngII, we observed a 
profound increase of CD1dhiCD5+ regulatory B cell subset only in mice infused with AngII. This was associated 
with a reduction in CD69 and CD44high expression by CD4+ T cells, suggesting that the expanded regulatory 
B cell population (under AngII) inhibited CD4+ T cell activation. Our data underlines the tight cooperation 
between adaptive T and B cell subsets40 in regulating atherogenic immune responses.
We identified IL-10 production by B cells as responsible for the atheroprotective phenotype of AngII-induced 
regulatory B cells, and revealed a requirement for both AngII and BAFF in promoting atheroprotective B10 cells. 
Therefore, our data indicate that B10 cells control atherosclerosis under defined conditions. There are several 
clinical settings where those conditions are met and may promote the generation of disease modulating B10 cells. 
It is noteworthy that in patients with active chronic sarcoidosis, elevated levels of BAFF and ACE were strongly 
associated with increased IL-10 producing B cells26, 41. CD20 mAb therapy in humans is known to increase BAFF 
levels and the naïve (CD19+IgD+), transitional or plasmablast (CD19+IgD+CD24hiCD38hi) B cells that recover 
after B cell depletion are responsive to BAFF and are associated with a better therapeutic effect42, 43. Interestingly, 
Figure 4. Regulatory B cells generated in response to AngII are atheroprotective through their production of 
IL-10. Apoe−/−/Baffr−/− mice were replenished with Il10+/+ or Il10−/− B cells and infused with AngII for 28 
days. (a) Quantitative analysis (left) and representative dot plots (right) of intracellular staining of IL10 in total 
splenocytes demonstrates a significant reduction of IL10 levels in mice transferred with Il10−/− B cells. n = 6 
mice per group. (b) Quantitative analysis (left) and representative dot plots (right) of intracellular staining 
of IL10 in splenic B cells demonstrates a significant reduction of B10 in mice transferred with Il10−/− B cells. 
n = 6 mice per group. (c) Quantitative lesion assessment by Oil Red O staining in the aortic sinus (left) and 
representative pictures (right) of Apoe−/−/Baffr−/− mice transferred with Il10+/+ or Il10−/− B cells and infused 
with AngII for 28 days (n = 6–8 mice per group). *p < 0.05. Scale bar 200 μm.
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regulatory B cells in humans are identified as CD19+CD24hiCD38hi44. In mice, additional membrane markers of 
regulatory B cells, non-investigated in our study, have been identified including TIM-145 and CD946. It is plausible 
that the B cells that regenerate after B cell depletion therapy acquire a regulatory phenotype due to high BAFF 
levels. Our results suggest that patients who undergo B cell depletion therapy would be protected from athero-
sclerosis and the B cells that regenerate in the presence of high BAFF and AngII (patients with atherosclerosis 
have high ACE activity) will enhance the protective effects due to their improved regulatory functions. Recently, 
Jackson et al. have reported another potential mechanism of atheroprotection induced by BAFF. Using several 
genetically modified mouse models on Apoe−/− background, they showed that BAFF overexpression increased 
anti-oxLDL IgM antibody plasma levels through TACI activation47. However, the functional effect of those B cell 
subsets in humans is yet to be explored. Increased BAFF level is associated with various autoimmune diseases 
and neutralizing BAFF is considered to be a potential therapeutic target for many of these diseases48. Our results 
show that therapeutic strategies aimed at neutralizing BAFF should be considered with caution since BAFF also 
downregulates immune responses through induction of IL-10. All our results were obtained in a BAFF receptor 
deficient environment and it is important to confirm them in other settings. In addition, as our study was per-
formed in mice at an early stage of atherosclerosis, further studies are required to confirm our findings in more 
advanced atherosclerosis.
Recently, Chan et al. reported a reduction of AngII-induced hypertension in Apoe−/−/Baffr−/− mice com-
pared with control Apoe−/−/Baffr+/+ mice. In addition, B cell supplementation in Apoe−/−/Baffr−/− mice worsened 
hypertension49. In our study, we found a slight but non-significant trend toward a lower increase of blood pres-
sure in Apoe−/−/Baffr−/− mice compared to Apoe−/− mice after infusion with AngII. B cell transfer into Apoe−/−/
Baffr−/− mice did not affect the blood pressure response to AngII infusion. This apparent discrepancy between 
our results and those of Chan et al. with regard to the hypertensive phenotype could be explained by the different 
doses of AngII used in the 2 studies (1 μg/kg/min or 1.4 mg/kg/day versus 0.7 mg/kg/day).
AngII infusion accelerates atherosclerosis and blockade of the renin-angiotensin system is protective. 
However, the proatherogenic effects of AngII have been shown to depend on age, sex, AngII dose, cholester-
olemia, duration of treatment and the arterial site at which lesion size was assessed50–52. Weiss et al. have shown 
that after 4 weeks of Ang II infusion, the increase of atherosclerotic plaque size was modest in the ascending 
Figure 5. Agtr1a deficiency in B cells accelerates AngII induced atherosclerosis in B cell replenished Apoe−/−/
Baffr−/− mice. (a) Agarose gel picture depicting Agtr1a gene expression in C57BL/6J WT, Apoe−/− and Apoe−/−/
Baffr−/− B cells and lack of expression in Agtr1a−/− B cells. Aorta and kidney samples were used as positive 
control. (b) Representative pictures (left) and quantitative lesion assessment by Oil Red O staining in the 
aortic sinus (right) and plasma cholesterol levels (c) of Apoe−/−/Baffr−/− mice replenished with Agtr1a+/+ or 
Agtr1a−/− B cells and infused with AngII for 28 days. n = 8 mice per group. (d) Quantitative analysis (left) 
and representative dot plots (right) of intracellular IL10 staining gated on splenic B220+ cells of Apoe−/−/
Baffr−/− mice replenished with Agtr1a+/+ or Agtr1a−/− B cells and infused with AngII for 28 days. n = 8 mice 
per group. (e) Quantitative measurements of Il10 mRNA in isolated C57Bl6 or Agtr1a−/− B cells treated in vitro 
in the presence or absence of AngII with or without pre-treatment with valsartan or PD98.059, antagonists of 
Agtr1a and ERK pathway, respectively. N = 4–6 per treatment condition and pooled data from 2 independent 
experiments. *p < 0.05, ns denotes non significance. Scale bar 200 μm.
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thoracic aorta and was much more pronounced in the descending thoracic and abdominal aorta53. Similarly, 
Zhou et al. found that the proatherogenic effect of AngII was much more important in the descending aorta than 
in the aortic sinus54. Lesion size was not statistically different between mice infused with PBS as compared to mice 
infused with AngII in Fig. 1a,b. However, experiments with and without AngII were not performed at the same 
time and should not be compared. When experiments with and without AngII were conducted simultaneously in 
immunodeficient apoe−/−Baffr−/− mice, we confirmed that AngII accelerated atherosclerosis in the aortic sinus. 
Interestingly, supplemention of apoe−/−Baffr−/− mice with B cells abrogated the pro-atherogenic effect of AngII 
due to expansion of an IL-10-producing B cell population. Together, the data suggest differential effects of AngII 
depending on the target cells, being pro-atherogenic in vascular cells and anti-atherogenic in immune cells, like 
B cells. Previous experiments using bone marrow transplantation in Ldlr−/− mice are in agreement with our 
findings. Cassis et al. found that AngII type 1A receptor engagement on vascular cells clearly promoted athero-
sclerosis, but the role of AngII type 1A receptor expressed by hematopoietic cells remained unclear14. This could 
be accounted for by the differential effects of AngII type 1A receptor engagement on different leukocyte subsets. 
For example, AngII may activate Th1 T cells10 but AngII type 1A receptor also limits M1 macrophage polari-
zation in part through a reduction of IL1 receptor activation15. Thus, the function of AT1A may not be solely 
proinflammatory. In our study, we found that AngII type 1A receptor activation induced a B10 regulatory profile. 
One of the pathways via which AngII mediates its cellular effects involves the activation of ERK downstream of 
AT1A38, 39. Furthermore, ERK activation is the common pathway utilized by most immune cells to induce IL-10 
production37. Our findings extend those results and provide evidence for an ERK-dependent induction of IL-10 
production by B cells in response to activation of AT1A receptor.
In summary, our results reveal a previously unsuspected synergistic role between AngII and BAFF in inducing 
atheroprotective B10 cells. Exploiting those pathways may lead to novel therapeutic strategies to limit atheroscle-
rosis in humans.
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